Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109


Modulation of the anti-cancer efficacy of microtubule-targeting agents by cellular growth conditions.

Dorsey JF, Dowling ML, Kim M, Voong R, Solin LJ, Kao GD.

Cancer Biol Ther. 2010 May 15;9(10):809-18.


6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells.

Levrier C, Sadowski MC, Rockstroh A, Gabrielli B, Kavallaris M, Lehman M, Davis RA, Nelson CC.

Mol Cancer Ther. 2017 Jan;16(1):3-15. doi: 10.1158/1535-7163.MCT-16-0325. Epub 2016 Oct 19.


Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells.

Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, Kao GD.

Mol Cancer Ther. 2004 Jun;3(6):661-9.


Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin.

Gan PP, McCarroll JA, Po'uha ST, Kamath K, Jordan MA, Kavallaris M.

Mol Cancer Ther. 2010 May;9(5):1339-48. doi: 10.1158/1535-7163.MCT-09-0679. Epub 2010 May 4.


Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.

Wang RC, Chen X, Parissenti AM, Joy AA, Tuszynski J, Brindley DN, Wang Z.

PLoS One. 2017 Aug 7;12(8):e0182400. doi: 10.1371/journal.pone.0182400. eCollection 2017.


Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents.

Dowling M, Voong KR, Kim M, Keutmann MK, Harris E, Kao GD.

Cancer Biol Ther. 2005 Feb;4(2):197-206. Epub 2005 Feb 8.


Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.

Perez EA.

Mol Cancer Ther. 2009 Aug;8(8):2086-95. doi: 10.1158/1535-7163.MCT-09-0366. Epub 2009 Aug 11. Review. Erratum in: Mol Cancer Ther. 2012 Jun;11(6):1381.


Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.

Verrills NM, Po'uha ST, Liu ML, Liaw TY, Larsen MR, Ivery MT, Marshall GM, Gunning PW, Kavallaris M.

J Natl Cancer Inst. 2006 Oct 4;98(19):1363-74.


Arsenic trioxide produces polymerization of microtubules and mitotic arrest before apoptosis in human tumor cell lines.

Ling YH, Jiang JD, Holland JF, Perez-Soler R.

Mol Pharmacol. 2002 Sep;62(3):529-38.


Bcl-xL is phosphorylated in malignant cells following microtubule disruption.

Poruchynsky MS, Wang EE, Rudin CM, Blagosklonny MV, Fojo T.

Cancer Res. 1998 Aug 1;58(15):3331-8.


βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.

Smiyun G, Azarenko O, Miller H, Rifkind A, LaPointe NE, Wilson L, Jordan MA.

Cancer Chemother Pharmacol. 2017 Jul;80(1):151-164. doi: 10.1007/s00280-017-3345-2. Epub 2017 May 31.


Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3.

Oliveras-Ferraros C, Fernández-Arroyo S, Vazquez-Martin A, Lozano-Sánchez J, Cufí S, Joven J, Micol V, Fernández-Gutiérrez A, Segura-Carretero A, Menendez JA.

Int J Oncol. 2011 Jun;38(6):1533-47. doi: 10.3892/ijo.2011.993. Epub 2011 Mar 30.


Preclinical efficacy spectrum and pharmacokinetics of ixabepilone.

Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW, Wiebesiek A, Vite G, Fairchild CR, Kramer R.

Cancer Chemother Pharmacol. 2009 Jan;63(2):201-12. doi: 10.1007/s00280-008-0727-5. Epub 2008 Mar 19.


Reversal of stathmin-mediated microtubule destabilization sensitizes retinoblastoma cells to a low dose of antimicrotubule agents: a novel synergistic therapeutic intervention.

Mitra M, Kandalam M, Sundaram CS, Verma RS, Maheswari UK, Swaminathan S, Krishnakumar S.

Invest Ophthalmol Vis Sci. 2011 Jul 23;52(8):5441-8. doi: 10.1167/iovs.10-6973.


A novel anti-microtubule agent with carbazole and benzohydrazide structures suppresses tumor cell growth in vivo.

Ohira M, Iwasaki Y, Tanaka C, Kuroki M, Matsuo N, Kitamura T, Yukuhiro M, Morimoto H, Pang N, Liu B, Kiyono T, Amemiya M, Tanaka K, Yoshida K, Sugimoto N, Ohshima T, Fujita M.

Biochim Biophys Acta. 2015 Sep;1850(9):1676-84. doi: 10.1016/j.bbagen.2015.04.013. Epub 2015 May 7.


[Microtubules and antineoplastic drugs].

Arioka H, Saijo N.

Gan To Kagaku Ryoho. 1994 Apr;21(5):583-90. Review. Japanese.


Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells.

Croix BS, Rak JW, Kapitain S, Sheehan C, Graham CH, Kerbel RS.

J Natl Cancer Inst. 1996 Sep 18;88(18):1285-96.


Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.

Chen YX, Wang Y, Fu CC, Diao F, Song LN, Li ZB, Yang R, Lu J.

Endocr Relat Cancer. 2010 Jan 29;17(1):39-50. doi: 10.1677/ERC-08-0296. Print 2010 Mar.


BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.

Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA.

Clin Cancer Res. 2001 May;7(5):1429-37.

Supplemental Content

Support Center